ChemoMetec (CHEMM) Q1 2025 earnings summary

Executive summary

• Revenue increased 27% year-over-year in Q1 2024/25 to DKK 115.6 million, driven by strong sales across instruments, consumables, and services.

• EBITDA rose 50% to DKK 62.1 million, with the EBITDA margin improving to 54% from 46% a year earlier.

• Growth was broad-based across geographies and product segments, with notable momentum in the USA/Canada and Europe.

Financial highlights

• Instrument sales surged 61% to DKK 39.2 million, accounting for 34% of total revenue.

• Consumables sales grew 13% to DKK 48.7 million, representing 42% of revenue.

• Services revenue increased 18% to DKK 26.7 million, making up 23% of total revenue.

• LCB business area revenue rose 29% and comprised 93% of total revenue.

Outlook and guidance

• Full-year 2024/25 revenue guidance maintained at DKK 445–460 million; EBITDA expected at DKK 222–230 million.

• Recent acquisition of Ovizio Imaging Systems SA is not expected to impact current profit guidance.